ImmunoGen Announces Webcast of Presentation and Q&A at the 35th Annual J. P. Morgan Healthcare Conference
Following the presentation,
A webcast of the presentation and question-and-answer session will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.
About ImmunoGen
ImmunoGen is a clinical-stage biotechnology
company that develops targeted cancer therapeutics using its proprietary
ADC technology. ImmunoGen's lead product candidate, mirvetuximab
soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant
ovarian cancer, and is in Phase 1b/2 testing in combination regimens for
earlier-stage disease. ImmunoGen's ADC technology is used in Roche's
marketed product, Kadcyla®, in three other clinical-stage
ImmunoGen product candidates, and in programs in development by partners
Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of
View source version on businesswire.com: http://www.businesswire.com/news/home/20161228005025/en/
Investor Contact:
sarah.kiely@immunogen.com
or
Media
Contacts:
amy.reilly@immunogen.com
or
FTI
Consulting, Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com
Source:
News Provided by Acquire Media